References
- Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, MD, USA (2011).
- Treseler PA, Clark OH. Prognostic factors in thyroid carcinoma. Surg. Oncol. Clin. N. Am. 6(3), 555–598 (1997).
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151–185 (2003).
- Suh I, Kebebew E. The biology of thyroid oncogenesis. Cancer Treat. Res. 153, 3–21 (2010).
- Laezza C, Mazziotti G, Fiorentino L et al. HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras–MAPK pathway. J. Mol. Med. 84(11), 967–973 (2006).
- Bifulco M. Therapeutic potential of statins in thyroid proliferative disease. Nat. Clin. Pract. Endocrinol. Metab. 4(5), 242–243 (2008).
- Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 88(7), 3021–3026 (2003).
- Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6(4), 292–306 (2006).
- Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19(9), 953–956 (2009).
- Catalano MG, Fortunati N, Pugliese M et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 90(3), 1383–1389 (2005).
- Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 462(7270), 175–181 (2009).
- Rothstein JD, Patel S, Regan MR et al. β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433(7021), 73–77 (2005).
- Gloeckner C, Garner AL, Mersha F et al. Repositioning of an existing drug for the neglected tropical disease onchocerciasis. Proc. Natl Acad. Sci. USA 107(8), 3424–3429 (2010).
- Zhang L, He M, Zhang Y, Nilubol N, Shen M, Kebebew E. Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. J. Clin. Endocrinol. Metab. 97(3), e319–e328 (2012).
- Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin. Investig. Drugs 20(10), 1357–1375 (2011).